The DSMB disclosed little in its statement, other than that a “target number of endpoint events had been reached,” while the Tra-2P trial's chairman, Dr Eugene Braunwald, was quoted as saying "It (vorapaxar) does not appear to be appropriate in patients who have had a stroke."
via seekingalpha.com
No comments:
Post a Comment